Homologous recombination deficiency (HRD) testing can provide crucial diagnostic information, including tBRCAm status, which can be used to personalise the treatment options for patients with newly diagnosed advanced ovarian cancer.1,2
HRD and BRCA tumour testing both analyse tumour tissue and have the same sample requirements. While tumour BRCA testing can identify tBRCA1/2 mutations, HRD testing identifies patients as HRD-positive by detecting BRCA1/2 mutations and measuring genomic instability.1,2
Both results are provided as part of the HRD test report, allowing decisions to be optimised in the patient treatment pathway. Therefore, moving forwards only a HRD test needs to be requested to inform treatment decisions for your patient.1
Homologous recombination deficiency is common in ovarian cancer.5 Approximately 1-in-2 women with advanced ovarian cancer have HRD-positive tumours (including those with a tBRCAm).5-7
Learn how to request a HRD test.
HRD test your advanced ovarian cancer patients at diagnosis to inform treatment decisions. 1,8-12 Earlier testing may support clinical management of advanced ovarian cancer and allows decisions to be personalised. Testing should be completed on the first available tissue, from biopsy (if one has been performed) or tissue from primary surgery.
All patients with newly diagnosed, advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer are eligible to be tested for HRD.1
To request a HRD test, please send a tumour tissue sample together with the completed test request form to one of the partner NHS Genomic Laboratory Hubs. It will be then forwarded to Myriad Genetics Inc. in the United States where the myChoice® CDx HRD test will be performed. The results will be returned to the GLH within 14-21 days for further dissemination to the requesting clinician.
The provision of the HRD testing service is funded by global co-promotion agreement between AstraZeneca & MSD. The service is delivered in accordance with arrangements agreed with NHS England and NHS Improvement and facilitated by NHS Genomic Laboratory Hubs.
To discuss HRD testing in the private sector, please contact us at: AZDiagnostics@astrazeneca.com.
The Myriad myChoice® CDx assay can identify patients as being HRD-positive by detecting tBRCA1/2 mutations and measuring genomic instability.2
Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW
Tel: 029 2184 2641
This content is valid for England, Wales and Northern Ireland; discussions for access to HRD testing in Scotland are ongoing. Updates to the website will be made periodically.
From the receipt of the tumour tissue sample to the GLH, Myriad Genetics Inc. will take approximately 14-21 days to perform the myChoice® CDx HRD test and return the results to the GLH for dissemination to the requesting clinician. Total time taken will be dependent on timely sample delivery to the GLH and GLH processing time.
HRD and tBRCA tumour testing both analyse tumour tissue and have the same sample requirements - for details please see the test request form for your local GLH. For the successful identification of patients' HRD status it is imperative that the acquisition and handling of tissue samples is carried out to the highest standards. This is essential for the results of HRD testing to successfully influence first line treatment decisions.2
Please refer to the Guide for Optimum Handling and Preparation of Tumour Samples for BRCA Testing for general information regarding the process of sample acquisition and handling.
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.1
Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with HRD positive status defined by either a BRCA1/2 mutation and/or genomic instability.1
Please see the Lynparza SmPC prior to prescribing for safety considerations to minimise the risks associated with the use of Lynparza.1